Kissei Pharmaceutical Co Ltd (JP:4547)
:4547
Want to see JP:4547 full AI Analyst Report?
Top Page
Kissei Pharmaceutical Co
(4547)
Select Model
Select Model
Rating:58Neutral
Price Target:
¥4,638.00
▲(0.61% Upside)
Action:Reiterated
Date:05/12/26
The score is primarily supported by strong balance-sheet safety, but is held back by inconsistent/negative cash flow and weakening operating performance. Technical indicators also reflect a clear near-term downtrend, while valuation and dividend yield offer modest support.
Positive Factors
Revenue Growth
Strong revenue growth indicates successful market penetration and demand for Kissei's products, supporting long-term business expansion.
Negative Factors
Cash Flow Generation
Low free cash flow generation relative to net income suggests potential challenges in converting earnings into cash, which may impact future investments.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Strong revenue growth indicates successful market penetration and demand for Kissei's products, supporting long-term business expansion.
Read all positive factors
Kissei Pharmaceutical Co (4547) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥179.32B
Dividend Yield2.48%
Average Volume (3M)67.88K
Price to Earnings (P/E)14.0
Beta (1Y)0.47
Revenue Growth10.28%
EPS Growth20.78%
CountryJP
Employees1,779
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)289.63
Shares Outstanding46,541,985
10 Day Avg. Volume76,260
30 Day Avg. Volume67,883
Financial Highlights & Ratios
PEG Ratio0.67
Price to Book (P/B)0.84
Price to Sales (P/S)1.98
P/FCF Ratio-30.35
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥5,500.00Price Target Upside19.31% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)284.57
Revenue Forecast (FY)¥99.48B
Kissei Pharmaceutical Co Business Overview & Revenue Model
Company Description
Kissei Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products primarily in Japan. It offers Urief and Urief OD tablets for the treatment of dysuria; Glufast, Glubes, and Marizev tablets for ...
How the Company Makes Money
Kissei primarily makes money by selling pharmaceuticals, with revenue generated from the commercialization of prescription drugs through medical institutions and wholesalers/distributors in its served markets. A key component of its earnings typic...
Kissei Pharmaceutical Co Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
88
Very Positive
Cash Flow
41
Neutral
| Breakdown | TTM | Mar 2026 | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 89.36B | 97.41B | 88.33B | 75.58B | 67.49B | 65.38B |
| Gross Profit | 44.26B | 45.82B | 44.06B | 37.34B | 32.38B | 31.24B |
| EBITDA | 20.37B | 1.72B | 20.25B | 18.72B | 17.81B | 20.26B |
| Net Income | 12.37B | 13.78B | 11.96B | 11.16B | 10.53B | 12.92B |
Balance Sheet | ||||||
| Total Assets | 243.67B | 275.09B | 244.06B | 260.93B | 221.20B | 238.09B |
| Cash, Cash Equivalents and Short-Term Investments | 48.75B | 54.42B | 48.65B | 45.93B | 49.60B | 53.15B |
| Total Debt | 1.77B | 1.25B | 1.60B | 1.73B | 1.95B | 1.98B |
| Total Liabilities | 35.43B | 43.55B | 33.93B | 39.79B | 26.38B | 35.91B |
| Stockholders Equity | 207.09B | 230.15B | 209.00B | 220.03B | 193.90B | 201.39B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -6.37B | 2.01B | -2.88B | -8.78B | 44.00M |
| Operating Cash Flow | 0.00 | -1.49B | 6.52B | -1.68B | -6.68B | 1.53B |
| Investing Cash Flow | 0.00 | 17.50B | 4.95B | 8.69B | 6.00B | 10.78B |
| Financing Cash Flow | 0.00 | -10.26B | -9.32B | -10.01B | -3.42B | -2.76B |
Kissei Pharmaceutical Co Technical Analysis
Positive
4610.00
Price Trends
4619.88
Positive
4573.42
Positive
4344.19
Positive
Market Momentum
60.17
Negative
60.86
Neutral
58.10
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4547, the sentiment is Positive. The current price of 4610 is below the 20-day moving average (MA) of 4713.97, below the 50-day MA of 4619.88, and above the 200-day MA of 4344.19, indicating a bullish trend. The MACD of 60.17 indicates Negative momentum. The RSI at 60.86 is Neutral, neither overbought nor oversold. The STOCH value of 58.10 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4547.
Kissei Pharmaceutical Co Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | ¥113.49B | 12.60 | 4.81% | 2.34% | 6.18% | 12.52% | |
69 Neutral | ¥73.91B | 27.41 | ― | 3.36% | -2.94% | -62.05% | |
59 Neutral | ¥207.15B | 13.89 | ― | 2.28% | 9.06% | -111.21% | |
58 Neutral | ¥179.32B | 14.03 | 6.70% | 2.48% | 10.28% | 20.78% | |
55 Neutral | ¥169.05B | 5.05 | 12.02% | 2.14% | 5.44% | -72.35% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | ¥152.18B | 73.21 | -2.58% | 4.16% | -18.25% | -84.71% |
* Healthcare Sector Average
JP:4547
Kissei Pharmaceutical Co
4,390.00
715.14
19.46%
JP:4521
Kaken Pharmaceutical Co
4,225.00
672.80
18.94%
JP:4553
Towa Pharmaceutical Co
3,435.00
674.15
24.42%
JP:4534
Mochida Pharmaceutical Co., Ltd.
3,335.00
424.01
14.57%
JP:4569
KYORIN Pharmaceutical Co.,Ltd.
1,404.00
1.59
0.11%
JP:4887
SAWAI GROUP HOLDINGS Co., Ltd.
2,082.50
354.80
20.54%
Kissei Pharmaceutical Co Corporate Events
Kissei Pharmaceutical Posts Record Sales as R&D Investment and Overseas Growth Intensify
May 12, 2026
Kissei Pharmaceutical reported record-high consolidated revenue for the fiscal year ended March 31, 2026, with net sales rising 10.3% year on year to ¥97.4 billion, driven by 3.5% growth in its pharmaceutical business and a 49.3% surge in oth...
Kissei Pharmaceutical Launches ¥6 Billion Share Buyback and Cancellation Plan
May 11, 2026
Kissei Pharmaceutical’s board has approved a share buyback of up to 1.3 million common shares, representing 3.14% of its outstanding stock, for a maximum of 6 billion yen. The repurchases will run from May 12 to December 31, 2026, via market...
Kissei Pharmaceutical Details FY2026 Results and R&D Pipeline in Supplementary Report
May 11, 2026
Kissei Pharmaceutical Co. released supplementary explanatory materials for its financial results for the fiscal year ended March 31, 2026, outlining key elements such as consolidated income statements, balance sheets and cash flow statements. The ...
Kissei Pharmaceutical Swings to Operating Loss but Lifts Payouts and Eyes Profit Recovery
May 11, 2026
Kissei Pharmaceutical reported fiscal 2026 net sales of ¥97.4 billion, up 10.3% year on year, but swung to an operating loss of ¥2.9 billion and an ordinary loss of ¥1.2 billion, while profit attributable to owners of parent rose 15...
Kissei sublicenses AML drug olutasidenib to Orient EuroPharma in Taiwan
May 1, 2026
Kissei Pharmaceutical has signed a sublicense agreement with Taiwan-based Orient EuroPharma to develop and commercialize the acute myeloid leukemia drug olutasidenib in Taiwan, building on their existing collaboration around diabetes drug Glufast....
Kissei Pharmaceutical Names Research Chief Keiji Miyazawa as New President and COO
Apr 24, 2026
Kissei Pharmaceutical has appointed Keiji Miyazawa as its new President and COO, effective June 23, 2026, pending approval at the regular shareholders’ and board meetings. Miyazawa, currently a board member and head of the Research Division ...
Kissei Launches Yselty in Japan, Expanding Global Uterine Fibroid Treatment Portfolio
Mar 19, 2026
Kissei Pharmaceutical has launched Yselty tablets 100mg, an orally administered GnRH antagonist (linzagolix choline), in Japan for the treatment of symptoms caused by uterine fibroids, such as heavy menstrual bleeding, pain and anemia. The company...
Kissei Pharmaceutical to Allocate ¥2.4 Billion in Treasury Shares to Employee Shareholding Plan
Feb 27, 2026
Kissei Pharmaceutical will dispose of up to 504,300 treasury shares as restricted stock to its Kissei Group Employee Shareholding Association, with a maximum disposal value of about ¥2.4 billion, via third-party allotment scheduled for August...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.